FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
about
Inhibition of acyl-coenzyme A:cholesterol acyltransferase stimulates cholesterol efflux from macrophages and stimulates farnesoid X receptor in hepatocytesBile acids, obesity, and the metabolic syndromeBile acid signaling in metabolic disease and drug therapyTrimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulationAgeing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASHFarnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone.Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitusDeciphering the nuclear bile acid receptor FXR paradigm.Tissue-specific function of farnesoid X receptor in liver and intestineDevelopment of a cell-based, high-throughput screening assay for cholesterol efflux using a fluorescent mimic of cholesterol.Deficiency of PXR decreases atherosclerosis in apoE-deficient mice.Walnut oil increases cholesterol efflux through inhibition of stearoyl CoA desaturase 1 in THP-1 macrophage-derived foam cells.Effects of FXR in foam-cell formation and atherosclerosis development.Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice.A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolismAnimal models of atherosclerosis.Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.Upregulation of decorin by FXR in vascular smooth muscle cells.Bile acids regulate cardiovascular functionFarnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic miceFXR signaling in metabolic disease.Inhibition of ileal apical but not basolateral bile acid transport reduces atherosclerosis in apoE⁻/⁻ miceNuclear receptors and inflammatory diseases.Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- miceMclk1+/- mice are not resistant to the development of atherosclerosis.FXR an emerging therapeutic target for the treatment of atherosclerosisFarnesoid X Receptor and Its Ligands Inhibit the Function of Platelets.Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.Deficiency of CCAAT/enhancer binding protein-epsilon reduces atherosclerotic lesions in LDLR-/- mice.Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome.Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target.Molecular biology of atherosclerosis.Bile acid receptors as targets for drug development.Scavenger receptor class B member 1 protein: hepatic regulation and its effects on lipids, reverse cholesterol transport, and atherosclerosis.Do the Apoe-/- and Ldlr-/- Mice Yield the Same Insight on Atherogenesis?Mechanisms of Action of Surgical Interventions on Weight-Related Diseases: the Potential Role of Bile Acids.The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Gut Microbiota and Atherosclerosis.
P2860
Q24648243-5A493C80-6C5F-4C61-BD1F-07E30193264EQ27020976-818712D9-A175-4ED5-BE67-963F45AE1AC1Q28244875-CF5FF42F-4D6C-4C51-861C-3B074694289AQ28283087-ACD8142D-55F4-4818-9F93-1111BCEB4621Q30454451-899DAEAA-A2AC-4670-B97E-450E2F462ADCQ34019132-125E5A43-FF11-4FC4-BB60-5E5FDF26E8AFQ34065876-B815C006-16B9-47F6-990C-A4272C48D480Q34081372-A58433B2-7B12-4A10-BF55-866B08DF36E9Q34626518-A0DD67BF-C3BA-4168-846B-BB090B7E8A27Q34714107-47923DDD-8B4C-4A33-BFED-D0BDB7B9E0EEQ34729735-C6A3B470-A937-41E3-BD73-2CA390F94B4AQ35152206-3F6D8AFA-AFF6-4D39-9F63-BBD8036C0C0FQ35232974-4E098DE1-63B3-4161-B64B-C337DFEB7820Q35546179-8583A395-8A06-4317-8484-A187D69B9FFBQ35744019-6500FE7F-0B61-458F-9431-0FE1FB09B58FQ35776935-57D5C493-CB3C-4512-906A-BC43C996ADD1Q35903298-473784D3-6C13-4C53-88A8-1CE11DB46AADQ36145170-5CC0A986-4C4A-4FC6-B8DC-D2B7AEFF3438Q36683297-2F2D75D0-93C6-4821-BF5B-D4A7C4712403Q36853007-9AF3FF83-9EAD-43CE-B4DB-97B2EF368CBEQ36995617-1E525EEB-53D6-4802-9564-1C7A1125B03DQ37002680-C4525242-1603-400D-BF2E-8535B4C32CDAQ37006382-3D57CAC4-09E4-4031-83D5-DFE57461DB59Q37047115-80723ED8-3D7D-48E1-B89B-93F87ADFA240Q37122891-209DBD19-8665-47EE-968C-C3D22599C7CDQ37190365-13601B5D-517A-4D4A-9D70-DAC7B0930D1EQ37196450-71A9DD43-DE4C-42AF-B105-F8ED57B232B0Q37334984-5FA0A88E-0B91-4F4E-8775-71DF680B3E54Q37485728-80CA28F0-D7FA-4D46-82B1-B4AC18DEFDDAQ37508029-4B8AA324-FB85-4674-B653-D675021A805BQ37525150-02B42040-FE83-4A72-BDA7-A74347BE9F63Q37900938-0A436968-BA57-420C-A9C5-B9F7E479E797Q37970350-C33084A6-94AB-435C-936C-1499941A1488Q38125279-C0CB36EE-2554-480B-B029-021E7CB4B055Q38132058-5124E454-91CC-4F0E-9872-DF99296C70B3Q38173740-F51ABB2D-E69F-4D6D-BF8B-B4A332B76859Q38888696-B7706DDB-72F0-4F97-A923-08EC4F9C9904Q39090294-BA6CDB52-F771-4CB6-8AA6-276E64A24BAFQ39262148-9EB565BD-A6C2-42E2-9546-668D0E545CC6Q40079055-A76AD6B3-31FB-4217-A5DB-8056A8B5F4DD
P2860
FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
@en
FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
@nl
type
label
FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
@en
FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
@nl
prefLabel
FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
@en
FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
@nl
P2093
P1476
FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
@en
P2093
Charisse Vales
Florence Ying Lee
Peter A Edwards
Xuping Wang
Yanqiao Zhang
P304
P356
10.1161/01.ATV.0000235697.35431.05
P407
P577
2006-07-06T00:00:00Z